ArticleMolecular cancer therapeutics2026
A Bispecific Anti-Fluorescein × Anti-CD3 T-cell Engager in Combination with Fluoresceinated Adaptors Enables Lysis of AML Cells.
Article in Molecular cancer therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DOTAM-TCB: Universal Small Molecule-guided Hapten- and T Cell-bispecific Antibodies for Cancer Immunotherapy.Antibody therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-targeting antibodies, antibody-drug conjugates, and radionuclide antibody conjugates are established therapeutic tools in clinical use. Furthermore, bispecific T cell-engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells are becoming the clinical standard of care in hemato-oncology and in some solid tissue neoplasms. To allow for on-off switching and targeting of multiple antigens, CAR T cells designed to recognize tumor-bound adaptor molecules (adaptor-CAR T cells) are now being investigated in clinical trials. We hypothesized that like adaptor-CAR T cells, a bispecific TCE recognizing CD3ε on T cells and fluorescein on tumor-bound adaptors would be able to direct T cells against target cells, potentially enabling multiplexing. We here show that a newly generated single-chain Fv-based anti-CD3 × anti-FITC construct (AdFITC-TCE) activates T cells toward acute myeloid leukemia (AML). Recognition of multiple targets through binding to fluoresceinated antibody constructs against CD33 and CD117 enables efficient tumor cell lysis in vitro. Moreover, we demonstrate that AdFITC-TCE plus fluoresceinated adaptors and T cells inhibit AML cell growth in NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ mice in vivo with similar efficacy as AdFITC-CAR T cells. Together, these data suggest that AdFITC-TCE, in combination with any given fluoresceinated binder, might be a versatile tool to activate T cells, leading to respective target cell lysis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.